Rounds / SiccaNova Therapeutics
STSiccaNova Therapeutics raises ¥1.25B (Series A)
Small-molecule drugs for exocrine gland dysfunction such as dry mouth.
- Company
- SiccaNova Therapeutics
- Reported
- 3 Sept 2026 · that week's brief
- Stage
- Series A · 「シリーズA」 · A
- Amount
- ¥1.25B1 · as announced: 「総額12.5億円」
- Breakdown
- Equity ¥1.25B
- Status
- In scopeNot yet registry-confirmed
- Investors
- Not listed in our summary; see source
- Sector
- BiotechDeep tech
- Source
- Primary release (PR TIMES) · BRIDGE coverage
1 ≈ ~$8.01M at the ECB reference rate on 2026-09-03 (¥1 = $0.00641). Yen is the figure of record. Methodology
Get the weekly brief
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →